Disruptions in Health: US Aid Freeze, Rising Measles, and Big Pharma Moves

Current health briefs highlight significant disruptions: US aid freeze affects HIV and malaria supply chains, FDA postpones rare disease events, and a leap in Texas measles cases. Meanwhile, Mirum Pharma's drug gets FDA approval, Eli Lilly invests in a weight-loss pill, and Pfizer halts a hemophilia gene therapy.

The global health landscape is facing significant disruptions, as a U.S. government foreign aid freeze impacts supply chains for HIV and malaria products. Products critical for battling diseases in impoverished regions experience life-threatening shortages, potentially persisting for months according to industry insiders.

Simultaneously, the FDA has delayed its rare diseases meeting and approved Mirum Pharmaceuticals' new genetic disorder treatment. In a further twist, Eli Lilly prepares to launch its weight-loss pill by stockpiling $550 million in inventory, even before completing its trial testing.

Troubling health outbreaks persist with the CDC reporting a five-fold spike in U.S. measles cases, mainly due to a growing Texas outbreak. On a corporate note, Pfizer is ceasing marketing for its hemophilia gene therapy due to low demand. Meanwhile, U.S. retail prices of eggs soar due to bird flu disturbances.

(With inputs from agencies.)